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1. Introduction  
Pancreatic cancer (PC) is the fifth leading cause of cancer death in the United States, with 
28,000 to 30,000 number of deaths annually (American Cancer Society,2002). 
Survival in patients with untreated pc is very poor, the one year survival rate is 19% and the 
5- year survival rate is 4% for all stages combined (American Cancer Society,2002). 
It must be emphasized that the majority of patients with pancreatic cancer are diagnosed in 
the metastatic phase; however when complete surgical resection with margin negative and 
node negative is possible, it offers the best opportunity for long survival or even cure, with 
5-year survival approaching 40% when performed at specialized center. (Sohn et al, 2000). 
Epithelial neoplasia of pancreas can be divided into those with predominantly exocrine 
differentiation and those with endocrine differentiation. 
Neoplasia of exocrine differentiation can be further subdivided into solid and cystic tumors; 
the majority of malignancies of the pancreas are solid infiltrating ductal adenocarcinomas.  
2. Histology  
About 80% of pancreatic malignancies are ductal adenocarcinomas, of which approximately 
70% occur in the head of the pancreas. 
A variety of uncommon types of pancreatic carcinoma have been described, including 
acinar, adenosquamous, anaplastic, papillary, mucinous and microadenocarcinomas, each of 
which composes less than 5% of the total. All of these have similarly poor prognoses and are 
treated in a similar fashion. Also uncommon are mucinous cystic neoplasms 
(cystadenoma/cystadenocarcinoma) of the pancreas, which occur most frequently in the 
middle-aged women, and these are tipically located in the tail of the pancreas. 
Clinical behavior can be difficult to predict pathologically, leading some to conclude that all 
mucinous cystic neoplasms of pancreas have malignant potential. 
Other rare neoplasms include pancreatoblastomas, most of which occur in children, primary 
lymphoma of the pancreas and metastasis.  
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3. Diagnosis of pancreatic neoplasia  
Currently, imaging modalities for detection of pancreatic masses include ultrasonography 
(US), computed tomography (CT) scan, magnetic resonance imaging (MRI)/ magnetic 
resonance cholangiopancreatography, endoscopic ultrasonography (EUS). 
In clinical practice differential diagnosis of pancreatic masses is frequently a clinical 
challenge; often therapeutic decision in this context is mainly based on the ability to perform 
a diagnosis of malignancy or to exclude malignancy (Tamm & Charnsangavej, 2001). 
It is well known that ductal adenocarcinoma is the most frequent cause of pancreatic mass, 
however other neoplasms such as lymphoma, metastasis, cystic tumors or benign conditions 
as chronic pancreatitis with different prognosis and treatment options can arise within the 
pancreas (Iglesias et al., 2010). 
A pathologic diagnosis becomes therefore relevant for an adequate therapeutic strategy 
(Cohen et al., 2000). 
At least 80% of the patients with suspected pancreatic cancer, have unresectable disease at 
diagnosis because of locoregional involvement or distant metastases , and it as been 
reported that only 7% of the patients have a tumour that is confined within the pancreas 
(National Cancer Institute, 2007). 
Patients with suspected pancreatic cancer and imaging studies suggesting resectable tumour 
should undergo directly to surgery since no histologic diagnosis confirmation is required 
prior to surgical exploration unless neoadjuvant therapy is indicated (Zamboni et al., 2010). 
As a matter of fact preoperative cytohistological diagnosis may risk dissemination of cancer 
cells, or developing complications (bleeding, pancreatitis, pancreatic leak) that can delay 
surgery and increase costs. 
On the other hand a negative biopsy results in a patient with a high suspicion of cancer 
neoplasm that is not of help, due to a high possibility of a false negative result (Tillou et al., 
1996). 
Patients with metastatic or locally advanced but unresectable disease at imaging studies 
should undergo biopsy prior chemotherapy or radiation since a cytohistological diagnosis is 
recommended before initiating a cytostatic therapy coherently with the National 
Comprehensive Cancer Network (NCCN) guidelines for suspected pancreatic cancer. 
(Hartwig et al, 2009; Itani et al., 1997) Biopsies allow a cytohistological diagnosis and can 
differentiate pancreatic cancer between primary pancreatic lymphoma (Arcari et al., 2005), 
metastasis or benign focal lesion such as focal pancreatitis.  
3.1 Primary pancreatic lymphoma and pancreatic metastasis  
Primary pancreatic lymphoma (PPL) is a very rare disease, representing fewer than 2% of 
extra-nodal malignant lymphoma and 0,5% of all pancreatic masses (Arcari et al., 2005). 
Fewer than 150 cases of PPL have been reported in the literature in English. Imaging 
techniques such as Us and CT scan can suggest a diagnosis of PPL but a cyto-hystological 
examination is mandatory for diagnosis and treatment planning of patients with suspicious 
PPL. Our group reported five cases of PPL and reviewing the literature it was concluded 
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that 1) imaging techniques can suggest the suspicion of PPL, however are unable to 
distinguish PPL from pancreatic adenocarcinoma, 2) histological diagnosis can be easily 
obtained by percutaneous Us-guided tissue core biopsy 3)surgery can be avoided both for 
diagnosis and therapy, but the treatment of choice of PPL may only be evaluated on a larger 
series of patients (Arcari et al., 2005). 
Metastases to the pancreas are rare; in a survey of 4,955 autopsies (Adsay et al., 2004) a rate 
of metastasis to the pancreas of 3,83% was described and a significantly different 
distribution of metastatic neoplasms, with lung and gastrointestinal tumors comprising by 
far the largest proportion. 
In a retrospective review of 1,172 pancreatic endoscopic ultrasound-guided fine-needle 
aspiration biopsy , 25 cases (2,1%) had a confirmed diagnosis of pancreatic metastasis.  
This included 12 cases of renal cell carcinoma, 3 (12%) melanomas, 3 (12%) small cell 
carcinomas and 7 (28%) other malignancies. 
In these metastatic tumors involving the pancreas 20 (80%) of the lesions were solitary. 
Four cases (16%) had no prior history of malignancy; the average time of diagnosis of 
pancreatic metastasis was 5.3 years. 
Immunohistochemistry and special stains were performed in 22 (88%) and 9 (36%) cases 
respectively (Gilbert et al., 2011).  
4. Staging of pancreatic cancer (table 1)  
Staging procedures include US, CT scanning, MRI, and EUS. A diagnostic laparoscopy may 
also be performed to detect peritoneal disease that is not visible radiologically. Regardless of 
these studies, an accurate histologic diagnosis is necessary to distinguish benign disease from 
carcinoma, islet cell tumors, and retroperitoneal lymphomas, because of the major therapeutic 
and prognostic differences among these disease entities. Criteria for surgical resection include 
absence of metastatic disease and absence of invasion of prominent local blood vessels.  
5. Guide for pancreatic biopsy  
Intraoperative needle biopsy of the pancreas has been performed with the fine-needle 
aspiration biopsy (FNAB) technique since the 1960’s (Moossa & Altorki, 1983) and with the 
core tissue biopsy technique since 1970’s (Ingram et al., 1978) subsequently ultrasound , 
computed tomography and endoscopic ultrasound became available to evaluate and 
characterize pancreatic masses and above all to guide a needle for the biopsy, avoiding the 
costs, morbidity and mortality of a major surgical procedure performed only to obtain a 
tissue sample for a cytohistological diagnosis (Civardi et al.,1986; Turner et a.l, 2010). 
For many years percutaneous US and /or CT guided biopsy was routinely performed in 
situations in which a pancreatic biopsy was necessary, in 2002 the American Joint 
Committee on cancer has selected endoscopic ultrasound guided FNAB as “the procedure of 
choice” if available (Greene et al., 2002). 
However, as recently reported, local expertise in and the availability of EUS and 
interventional radiology may determine the first procedure selected for a cytohistological 
diagnosis for a pancreatic mass (Zamboni et al., 2010 ).  
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Prymary Tumor (T)  
TX Primary tumor cannot be assessed 
T0 No evidence of primary tumor 
Tis In situ carcinoma 
T1 Tumor limited to the pancreas 2 cm or less in greatest dimension 
T2 Tumor limited to the pancreas more than 2 cm in greatest dimension 
T3 Tumor extends beyond the pancreas but without involvement of celiac 
axis or the superior mesenteric artery 
T4 Tumor involves the celiac axis or the superior mesenteric artery 
(unresectable primary tumor)   
Regional Lymph Nodes (N)  
NX Regional lymph nodes cannot be assessed  
N0 No regional lymph node metastasis  
N1 Regional lymph node metastasis    
Distant Metastasis (M)  
MX Distant metastasis cannot be assessed  
M0 No distant metastasis  
M1 Distant metastasis 
Stage grouping  
Stage 0 Tis  N0  M0 
Stage IA T1 N0 M0 
Stage IB T2 N0 M0 
Stage IIA T3 N0 M0 
Stage IIB T1-3 N1 M0 
Stage III T4 Any N M0 
Stage IV Any T Any N M1  
Table 1. Staging of pancreatic carcinoma  
5.1 Methods of percutaneous guided biopsy  
Patient preparation before any type of invasive procedure includes ruling out coagulation 
disorders with laboratory tests and obtaining written informed consent for the biopsy. Local 
anesthesia (lidocaine) is not routinely performed. (Zamboni et al., 2010; Civardi et al., 1986).  
5.2 Percutaneous ultrasound   
In the past for performing abdominal US-guided FNAB the “free-hand” technique was 
utilized (Civardi et al., 1986; Bret et al., 1982; Livraghi, 1984) subsequently puncturing probe 
became available and two types of probes are commonly used for interventional procedures: 
probes with lateral support and probes with noncontinuous crystals and central support; the 
former allow only oblique needle tracks, whereas the latter allow both vertical and oblique 
tracks. 
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Prior to perform the biopsy, a pancreatic lesion can be studied with conventional US, 
Doppler US, and CT, to evaluate the content of the lesion and to select the best route for 
biopsy, avoiding vessels and pleura. 
In clinical practice when liver metastases are present in patients with suspected pancreatic 
cancer, the biopsy can be done in the liver metastasis, if safer for the patient and easier for 
the psysician.  
5.3 Computed tomography 
Computed tomography allows optimal visualization of the lesion and is superior to US in 
large fat patients , however radiation dose and the procedure length are the major limits of 
CT -guided pancreatic biopsy. 
CT fluoroscopy can reduce procedure length because it allows a fast reconstruction of 
images, with a continuous update and the possibility of controlling acquisition and 
visualizing images in the room while performing the examination.  
In addiction CT fluoroscopy allows visualizing the needle track from the entry point to the 
target, allowing faster and more efficient procedure (Zamboni et al., 2010).  
5.4 Endoscopic ultrasound  
Over the past decade, EUS has proven to be one of the most significant advantages in 
gastrointestinal endoscopy (Turner et al., 2010; Erickson, 2004) Since its introduction, EUS 
has offered improved accessibility to small pancreatic lesions, and its usefulness as a 
diagnostic tool has greately changed the therapeutic approach to pancreatic masses. 
Since it was first reported in (Chang et al, 1994), EUS-guided FNAB of the pancreas has 
become a popular technique for the diagnosis and staging of cystic and solid lesions of the 
pancreas because it is relatively safe and accurate (Carrara et al., 2010;). 
Thus, this diagnostic modality has become important in the management of patients with 
symptomatic or incidentally discovered pancreatic masses.  
5.4.1 US, CT, or EUS for guide pancreatic FNAB  
The relative diagnostic accuracy, safety and cost of US and CT-guided FNAB favor their use 
over EUS-FNAB for the diagnosis of unresectable pancreatic tumors. (Zamboni et al., 2010 ; 
Levy, 2006). 
A randomized controlled trial EUS-FNAB and US/CT-FNAB failed to observe any 
statistically significant difference between the endoscopic and percutaneous approach in the 
diagnosis of pancreatic malignancy (Horwhat et al.,2006). 
Several authors support the use of EUS-FNAB over percutaneuos approach because of the 
lower risk of seeding (Gilbert et al, 2001; Turner et al, 2010). In a review of 1406 cases with 
advanced pancreatic cancer who underwent nonsurgical biopsy (percutaneous-guided or 
EUS-guided sampling) were compared with cases who did not undergo biopsy, without 
observing any difference in overall median survival, so it was concluded that the risk of 
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seeding is remote. (Hernandez et al., 2009). It was reported that the risk of seeding can be 
related to the number of needle passes: more number of needle passes more risk of seeding 
(Civardi et al., 1986; Fornari et al., 1989). 
It must be emphasized that one-site cytopathological evaluation can improve the diagnostic 
yield of guided FNAB and can reduce the number of needle passes (Garcia et al., 2011). 
A review of 182 patients undergoing EUS-guided FNAB of solid pancreatic lesions over a 2 
years study period was reported (Garcia et al., 2011). Sample were either evaluated on site 
by a cytopathologist or processed by the endoscopist and sent to the pathology department 
for evaluation. 
Diagnostic accuracy for malignancy, number of needle passes, adequate – specimen 
collection rate, cytological diagnosis , and final diagnosis and complications rate according 
to the presence or absence of on-site cytopathologist were evaluated. 
A significantly higher number of needle passes was performed when an on-site 
cytopathologist was not available (3.5+- 1.0 vs 2.0+-0.7; p< 0.001). The presence of an on-site 
cytopathologist was associated with a significant lower number of inadequate samples (1.0 
vs 12.6%; p=0.002) and a significantly higher diagnostic sensivity (96.2 vs 78.2%; p=0.002), 
and overall accuracy (96.8 vs 86.2%; p=0.013) for malignancy (Garcia et al., 2011). 
Already, in 1988 our group reported the value of rapid staining and assessment of 
percutaneous ultrasound-guided fine needle aspiration biopsy in a series of 160 patients. 
(Civardi et al., 1988) The total series of FNAB had a sensitivity of 95.6%, a specificity of 100% 
and an overall accuracy of 97.3%. 
The cumulative accuracy after each pass was calculated: a significant increase in diagnostic 
accuracy was found only after the second pass, the third and the fourth passes gave little 
further improvement. These results indicate that a rapid evaluation of the aspirated material 
during US-guided FNAB can reduce the number of punctures needed per case resulting in 
less disconfort and, probably a reduced likelihood of complications for the patient. 
It must be emphasized that in this study the same physicians that performed the US-FNAB 
performed also the rapid staining evaluation for the adequacy avoiding the cytopathologist, 
minimizing the costs and improving the educational benefit of physicians. (Civardi et al., 
1988).  
5.4.2 Type of needle and results of guided biopsy  
Biopsies of the pancreas can be performed with needle ranging in size from 18 to 25 gauge 
(G). Aspiration biopsies for cytological evaluation are performed with fine-needle (< 1mm in 
external diameter : from 20 to 25 G), cutting needle are used to obtain tissue cores, which 
allow hystopathological evaluation , these needle ranging in size from 18 to 23 G. 
In table 2 are reported the results of sensitivity, specificity, overall accuracy, method of 
guidance, needle size of percutaneous pancreatic fine-needle aspiration biopsy. 
Our group (Di Stasi et al., 1998) in a multicenter study reviewed 510 patients who had a final 
diagnosis available and who had undergone ultrasound-guided fine needle biopsy of the  
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510 87 100 95 US 21-22 
Di Stasi et al 
(1998) 
267 81 - - US 22 
Bhatia et al 
(2008) 
222 89 98 91 US 22 (20,25) 
Garre Sanchez  
et al (2007) 
104 77.9 100 81.7 US - 
Volmar et al; 
Zamboni (2005) 
70 80 100 81 CT/US - 
Mallery et al 
(2002) 
59 93 100 93 US 22 
Matsubara et al 
(2008) 
50 78.6 100 82 CT - 
Volmar et al 
(2005) 
36 62 100 72 CT/US 20-22 
Horwhat et al 
(2006) 
545 99.4 - 99.4 US 21-22 
Zamboni et al 
(2010) 
Table 2. Sensitivity, specificity, accuracy method of guidance and needle size (gauge) of 
percutaneous fine needle aspiration biopsy of pancreatic masses  
pancreas. Retrieval rate, sensitivity, specificity, and overall diagnostic accuracy of the whole 
series, by three different bioptic procedures (cytology, histology and cytology plus 
histology) were evaluated. The reliability of ultrasound-guided fine needle biopsy to allow a 
correct diagnosis in the different pancreatic pathologies was calculated for cytology, 
histology, and cytology plus histology, retrieval rate values were: 94%, 96%, and 97%; 
sensitivity was: 87%, 94%, and 94%, specificity:100%; and diagnostic accuracy: 91%, 90% and 
95%, respectively.  
In a series of 545 US-guided FNAB, 93,4% procedures were diagnostic, with an overall 99,4% 
sensitivity and 99.4% accuracy (Zamboni et al., 2010). 
The largest series reporting in the literature percutaneous FNAB of pancreatic masses show 
sensitivities ranging between 62% and 93%, accuracies between 72% and 94%. The majority 
of percutaneous FNAB are ultrasound guided, and the needle size range from 21 to 22 G 
(Tab 2). 
FNAB cytology of pancreatic cancer are reported in figure 1 a , b, 2 a, b, 3 a, b;   
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Fig. 1. a. FNAB of pancreatic well-differentiated adenocarcinoma, (a) relatively mild nuclear 
atypia, but nuclear crowding. MGG x 200  
 
 
Fig. 1. b. Well evident microglandular arrangement. PAP x 400 
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Fig. 2. a. FNAB of pancreatic moderately differentiated pancreatic adenocarcinoma.  
MMG x 200  
 
 
Fig. 2. b. Clusters of cells with some acinar arrangement. PAP x 400   
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Fig. 3. a. FNAB of pancreatic poorly differentiated pancreatic adenocarcinoma, a cluster of 




Fig. 3. b. Cancer cells with strong reactivity to CK 7 antiboby. X 400   
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and FNAB cytology of pancreatic metastasis is reported in figure 4 a, b.    
 
Fig. 4. a. FNAB of pancreatic mass showing metastatic melanoma large cells. MGG x 400  
 
  
Fig. 4. b. Immunocytochemical HMB-45 positivity consistent with metastatic melanoma X 400  
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Sensitivity, specificity, accuracy method of guidance and needle size of percutaneous tissue 














372 90 - 90 CT 18 
Amin et al 
(2006) 
212 86 100 86 US 21 
Matsubara 
 et al 
(2008) 




100 90 - - US - 
Karlson et al 
(1996) 
92 92.5 100 93.3 US 18 
Paulsen et al 
(2006) 
50 90.4 - 92 US - 
Elvin et all 
(1990) 
18 100 1 100 CT 18 
Paulsen et al 
(2006) 
Table 3. Sensitivity, specificity, accuracy method of guidance and needle size (gauge) of 
percutaneous tissue core biopsy of pancreatic masses  
372 CT-guided pancreatic biopsies with a 18 G cutting needle showed 90% sensitivity and 
accuracy (Karlson et al., 1996); similar results were reported in a series of 212 US guided 
percutaneous tissue core pancreatic biopsies, with 86% sensitivity and accuracy (Paulsen et 
al., 2006). 
The largest series in the literature on percutaneous tissue core biopsy of pancreatic lesions 
report sensitivities and accuracies between 86% and 100% (Tab 3). Tissue core biopsy of 
primary pancreatic lymphoma and metastatic adenocarcinoma are reported in fig 5 a b and 
6 a b c. Percutaneous core biopsy of pancreatic lesions is considered sensitive, safe and 
accurate (Zanaboni et al., 2010) however this procedure may have a higher complication rate 
than percutaneous FNAB (Fornari et al., 1989). 
At our institution we routinely use FNAB with 22G needles when a pathologic diagnosis of 
pancreatic mass is required while tissue core biopsy with 20G or 21G needles is reserved 
when cytological diagnosis is inadequate or when lymphoma is suspected on cytological 
evaluation (Arcari et al., 2005) Fig 5 a, b.   
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Fig. 5. b. Diffuse large B-cell Lymphoma CD20 positive. X 400  
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Fig. 6. a. Tissue core biopsy of a pancreatic mass. H&E x 20   
 
Fig. 6. b. Histology shows metastasis from endometrial adenocarcinoma. H&E X 100  
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Fig. 6. c. Estrogen receptor positive neoplastic cells. X100  
Since it was developed endoscopic ultrasound-guided fine needle aspiration biopsy has 
been widely used and has been adapted for gastrointestinal and perigastrointestinal lesions. 
A medical literature review to evaluate the role of EUS-FNAB for diagnosis of pancreatic 
masses showed a 78-95% sensitivity, 75-100% specificity, 98-100% positive predictive value 
and a 78-95% accuracy (Yoshinaga et al, 2011) (Tab 4).   
N of patients Sensitivity % Specificity % Accuracy% Needle size Authors 
583 84 86 84 22-26 
Siddiqui  
et al (2011) 
100 78 75 78 22 
Touchefeu  
et al (2009) 
182* 78.2-96.2* 98.4 86.2-96.8* 22 
Garcia  
et al (2011) 
737 77 99 80 22-25 
Turner 
et al (2010) 
207 92.6 88.6 91.8 22 
Klimet  
et al(2010) 
* The presence of an on site-cytopathologist was associated with a significantly higher diagnostic 
sensitivity and overall accuracy for malignancy.  
Table 4. Sensitivity, specificity, accuracy needle size of endoscopic-guide pancreatic biopsy  
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6. Complications of pancreatic biopsy  
US, EUS or CT guided fine-needle biopsy are considered to be a low risk procedure. 
Interventions with needle with a larger diameter seem cause more complications. 
The major complication of pancreatic biopsy can be hemorrhage, needle track seeding and 
pancreatitis. 
Our group (29) reported the complications following 10.766 US-guided fine-needle abdominal 
biopsies. The mortality was 0.018%: the two reported deaths were due to hemoperitoneum and 
occurred in patients with hepatocellular carcinoma arizing in cirrotic liver. 
The biopsy of pancreatic carcinoma was more dangerous for needle –track seeding (five of eight 
reported cases), however, it has been reported that peritoneal carcinomatosis may occur more 
frequently in patients who undergo percutaneous FNAB compared with those who have FUS-
FNAB for the diagnosis of pancreatic cancer (Micames et al, 2003).  
6.1 Conclusions  
There is consensus in the literature of the appropriateness of obtaining a cytohystological 
diagnosis in patients with unresectable pancreatic neoplastic lesion, prior to initiate 
chemotherapy and/or radiation. 
Although the American Joint Committeee on Cancer has selected EUS-guided FNAB as the 
procedure of choice, if available, we recall that there is wide variability in the world on the 
modalities for guide biopsy (US ; CT ; EUS) and for needle biopsy choice (FNAB or tissue 
core biopsy). 
There is a consensus that local expertise, the availability of EUS and interventional percutaneous 
procedures may determine the choice for pancreatic biopsy. 
In agreement with other authors (Zamboni et al., 2010) at our institution , in the appropriate 
setting, percutaneous US-guided FNAB is considered the first invasive approach of obtaining 
tissue diagnosis confirmation in patients with unresectable lesions. 
However, guided FNAB or guided tissue core biopses remain invasive procedures and must be 
performed when informations so obtained benefits the patient.  
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